Abstract
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Keywords: Receptor, channel, patch clamp, kinetics
Current Neuropharmacology
Title: Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids
Volume: 8 Issue: 1
Author(s): Gustav Akk, Douglas F. Covey, Alex S. Evers, Steven Mennerick, Charles F. Zorumski and Joe Henry Steinbach
Affiliation:
Keywords: Receptor, channel, patch clamp, kinetics
Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Export Options
About this article
Cite this article as:
Akk Gustav, Covey F. Douglas, Evers S. Alex, Mennerick Steven, Zorumski F. Charles and Steinbach Henry Joe, Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909458
DOI https://dx.doi.org/10.2174/157015910790909458 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Prospects for Caspase Inhibitors
Mini-Reviews in Medicinal Chemistry Synthesis and Anticonvulsant Effect of Novel Thiazolidinedione Containing Benzene-sulfonylurea and Sulfonylthiourea Derivatives
Central Nervous System Agents in Medicinal Chemistry Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases
Current Medicinal Chemistry - Central Nervous System Agents Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling
Current Genomics Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Editorial [Hot Topic: Dopaminergic Neurotransmission (Guest Editor: Remco H.S. Westerink)]
CNS & Neurological Disorders - Drug Targets Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors
Current Alzheimer Research Maternal Sodium Valproate Exposure Alters Neuroendocrine-Cytokines and Oxido-inflammatory Axes in Neonatal Albino Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets The Natural Diatomite from Çaldıran-Van (Turkey): Electroanalytical Application to Antimigraine Compound Naratriptan at Modified Carbon Paste Electrode§
Combinatorial Chemistry & High Throughput Screening Melatonergic Drugs for Therapeutic Use in Insomnia and Sleep Disturbances of Mood Disorders
CNS & Neurological Disorders - Drug Targets An Eco-friendly Solvent-free Synthesis of Trisubstituted Methane Derivatives Catalyzed by Magnetic Iron Oxide Nanoparticles as a Highly Efficient and Recyclable Catalyst
Letters in Organic Chemistry Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Clinical Pharmacotherapy for Obesity: Current Drugs and Those in Advanced Development
Current Drug Targets HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
Infectious Disorders - Drug Targets Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry